Abstract:Interleukin 17A (IL-17A) exerts pleiotropic effects on periodontitis, partially through enhancement of alveolar bone loss. Osteoclasts are the main culprits that absorb alveolar bone. However, studies describing the correlation between IL-17A and osteoclasts are not conclusive. Previously, autophagy was revealed to be involved in osteoclast differentiation and bone resorption. However, the role of autophagy in IL-17A-mediated osteoclast formation is yet to be clarified. In the present study, bone marrow macrophages (BMMs) were treated with or without IL-17A. 3-Methyladenine (3-MA) was applied to inhibit autophagy. Osteoclast formation was detected by tartrate-resistant acid phosphatase (TRAP) staining, immunofluorescence, and scanning electron microscope. The effects of IL-17A on osteoclast-specific genes and autophagy-related genes during osteoclast differentiation were examined by real-time quantitative polymerase chain reaction and western blot analysis. Autophagosomes were observed by transmission electron microscope. Hematoxylin and eosin (H&E), and TRAP staining was adopted to assess alveolar bone destruction and the number of osteoclasts, respectively in a rat periodontitis model. Consequently, IL-17A stimulated osteoclast differentiation and bone resorption of BMMs accompanied by an increase in the mRNA expression of osteoclast-specific genes. Furthermore, IL-17A increased the levels of autophagy-related genes and proteins, and inhibition of autophagy with 3-MA attenuated the IL-17A-mediated osteoclastogenesis. In addition, there was an increase in the number of osteoclasts and alveolar bone resorption with IL-17A treatment in the periodontitis rat model. Collectively, these findings indicated that IL-17A facilitated osteoclast differentiation and bone resorption in vitro and in vivo, which may contribute to the understanding of the molecular basis of IL-17A in alveolar bone destruction and provide insight on the clinical therapeutic targets for periodontitis.

Interleukin-37 Inhibits Osteoclastogenesis and Alleviates Inflammatory Bone Destruction

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Interleukin-27 Prevents LPS-induced Inflammatory Osteolysis by Inhibiting Osteoclast Formation and Function.

The emerging role of Interleukin 37 in bone homeostasis and inflammatory bone diseases

Interleukin‑17A facilitates osteoclast differentiation and bone resorption via activation of autophagy in mouse bone marrow macrophages.

A Novel Inhibitor INF 39 Promotes Osteogenesis Via Blocking the NLRP3/IL-1β Axis

Interleukin-35 Inhibits TNF-α-Induced Osteoclastogenesis and Promotes Apoptosis Via Shifting the Activation from TNF Receptor-Associated Death Domain (TRADD)–TRAF2 to TRADD–Fas-Associated Death Domain by JAK1/STAT1

Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K/AKT signaling pathway

The Elevated Expression of IL-38 Serves As an Anti-Inflammatory Factor in Osteoarthritis and Its Protective Effect in Osteoarthritic Chondrocytes.

Interleukin-35 Upregulates OPG and Inhibits RANKL in Mice with Collagen-Induced Arthritis and Fibroblast-Like Synoviocytes.

The emerging role of IMD 0354 on bone homeostasis by suppressing osteoclastogenesis and bone resorption, but without affecting bone formation

The Protective Effect of Interleukin-37 on Vascular Calcification and Atherosclerosis in Apolipoprotein E-Deficient Mice with Diabetes

Interleukin‐35 protein inhibits osteoclastogenesis and attenuates collagen‐induced arthritis in mice

Molecular Basis of Requirement of Receptor Activator of Nuclear Factor Κb Signaling for Interleukin 1-Mediated Osteoclastogenesis.

Interleukin-21 Promotes Osteoclastogenesis in RAW264.7 Cells Through the PI3K/AKT Signaling Pathway Independently of RANKL.

IL-17A inhibits the degradation of RANKL in osteoblasts by inhibiting BCL2-Beclin1-autophagy signaling

LL-37 inhibits LPS-induced inflammation and stimulates the osteogenic differentiation of BMSCs via P2X7 receptor and MAPK signaling pathway.

Interleukin-37 Inhibits Interleukin-1β-Induced Articular Chondrocyte Apoptosis by Suppressing Reactive Oxygen Species

Targeting Integrin-β1 Impedes Cytokine-Induced Osteoclast Differentiation: A Potential Pharmacological Intervention in Pathological Osteolysis

IL-37 Blocks Gouty Inflammation by Shaping Macrophages into a Non-Inflammatory Phagocytic Phenotype.

Interleukin-10 Inhibits Bone Resorption: A Potential Therapeutic Strategy in Periodontitis and Other Bone Loss Diseases